nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Addiction/Reward"

 

FDA Permits Marketing of Mobile Medical Application for Substance Use Disorders
September 20, 2017   

The US FDA has permitted the marketing of the Reset device, the first mobile medical application to help treat substance use disorders...
 Continue reading (Members only)
Evaluating the Evidence for Cannabis as a Therapeutic Option: Focus on Chronic Pain and PTSD
September 7, 2017   

As the medicinal use of cannabis becomes increasingly accepted and legal--at least at the state level--a major concern for the medical community is: what is the evidence regarding the efficacy and safety of cannabis as a treatment for medical and psychiatric disorders? Two recent reviews, commissioned by the Veterans Health Administration and funded by the US Department of Veterans Affairs, addressed this issue specifically for chonic pain and posttraumatic stress disorder (PTSD)...
 Continue reading
Controlling Pain Without Medication: Mindfulness-Oriented Recovery Enhancement (MORE)
July 7, 2017   

Long-term opioid use may lead to an increased risk of aberrant-medication related behaviors among patients who suffer from chronic pain. Risk of opioid misuse and addiction is a growing concern, but a new approach may prove to help patients suffering from both chronic pain and opioid misuse....
 Continue reading
Update on Substance Abuse and Addictions
June 26, 2017   

At the recent 2017 American Psychiatric Association (APA) Annual Meeting, the topic of substance abuse and addiction was the focus of several sessions, lectures, and posters. Some of the highlights from the conference include...
 Continue reading
Highlights from the 2017 APA Annual Meeting
June 8, 2017   

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.
 Continue reading
Marijuana Use in Pregnant Women Has Increased
January 13, 2017   

In a recent observational study, the prevalence of marijuana use in pregnant versus nonpregnant women was examined...
 Continue reading (Members only)
Increase in Opioid-Related Deaths Not Driven By Prescription Painkillers
January 12, 2017   

Opioid abuse remains an epidemic in the United States, with over 50,000 deaths associated with drug overdose, and 63% of those attributed to opioids...
 Continue reading (Members only)
FDA Update: Boxed Warnings in Varenicline and Bupropion Labels to Be Removed
December 19, 2016   

The results of a large clinical trial required by the FDA have shown that the risk of mental health side effects with the smoking cessation agents Chantix (varenicline) and Zyban (bupropion) is lower than previously thought...
 Continue reading (Members only)
FDA Approves Trials for MDMA as Treatment for PTSD
December 14, 2016   

As many as 24.5% of Iraq and Afghanistan veterans may suffer with posttraumatic stress disorder (PTSD), a disorder characterized by re-experiencing, avoidance, arousal, and changes to mood and cognition. Available pharmacological treatments approved for treating PTSD (sertraline and paroxetine) have very limited efficacy...
 Continue reading
SAMHSA Report: Results from the 2015 National Survey on Drug Use and Health
October 5, 2016   

In 2015, the National Survey on Drug Use and Health (NSDUH) was administered to people aged 12 and older in the United States, to collect data on indicators of substance use and mental health in this population...
 Continue reading (Members only)
123
Top of Page